Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics

by Ysios Capital

5 years ago
Vivet Therapeutics, Pfizer, Wilson disease, Ysios Capital

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfize...

Galecto Biotech Raises €79 Million in Series C Financing Co - Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late - Stage Clinical Development

by Ysios Capital

6 years ago
Ysios Capital, Galecto Biotech, Galectin-3, TD139, OrbiMed

Galecto will use the proceeds to conduct a phase 2/3 clinical study of inhaled TD139, a potent and selective inhibitor of galectin - 3, in idiopathic pulmonary f ibr osis (IPF), a chronic and se vere ...

Minoryx Therapeutics raises €21.3M in Series B funding round

by Ysios Capital

6 years ago
Minoryx Therapeutics, MIN-102, adrenomieloneuropatía

The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs. Ysios Capital participates in the round

by Ysios Capital

7 years ago
Xeltis, Ysios Capital, aortic valve, biomaterials

Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C finan...

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

by Ysios Capital

7 years ago
Kala Pharmaceuticals, Ysios Capital, dry eye disease

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary MPP technology, with an initial focus on the treatment of eye diseases. Kala ...

Ysios Capital lidera una ronda de 5,5M EUR en la estadounidense Babyscripts

by Ysios Capital

7 years ago
Ysios Capital, Babyscripts, Chemo Group, CG Health Ventures, Aurora Healthcare Ventures, P5 Health Ventures

Ysios Capital ha liderado la ronda de financiación de 5,5 millones de dólares, a la que también se han sumado nuevos inversores como Chemo Group, compañía especializada en la salud de la mujer, C...

Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds

by Ysios Capital

7 years ago
Anaconda Biomed, Ysios Capital, Banc Sabadel, Omega Funds, Innogest Capital, ANCD BRAINTM

Anaconda Biomed, a pre-clinical stage medical device company focused on the development of the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today ann...

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

by Ysios Capital

Vivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financ...

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

7 years ago
Ysios Capital, BioClin Therapeutics, Sofinnova Ventures, HealthCap, Life Science Partners, Tekla, Caixa Capital Risc, BioFund II

The financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...

MedLumics secures 34.4 million euros in Series B Funding

by Ysios Capital

7 years ago
MedLumics, cardiac device, AblaView catheter, atrial fibrillation, arrhythmias, Ysios Capital, Caixa Capital Risk

MedLumics, a cardiac device company specializing in optically guided minimally invasive instruments, announced today that it has raised 34.4 million Euros in financing that will be used to help advanc...

TiGenix raises $35.65 million gross proceeds with NASDAQ IPO

by Ysios Capital

7 years ago
TiGenix, Ysios Capital

TiGenix, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the pricin...

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

8 years ago
OxThera, Oxabact®, Primary hyperoxaluria, Ysios Capital, kidney deterioration, calcification of soft tissues

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If...